Sign In
Buy KRYS
$301.82
+8.61 (+2.94%)
At Close: Jun 03, 2026
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer
08:00am, Wednesday, 18'th Dec 2024
Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful repea
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408
12:11pm, Friday, 13'th Dec 2024
Krystal Biotech posts initial clinical updates on its two pipeline candidates, KB407 and KB408, which are being developed to treat rare respiratory diseases.
Krystal Biotech Provides Update on EMA's Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa
04:15pm, Monday, 09'th Dec 2024
CHMP opinion now expected in 1Q 2025 No Major Objections outstanding; continue to expect Germany launch in 2Q 2025 PITTSBURGH, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company�
Why Is Krystal Biotech (KRYS) Up 6.6% Since Last Earnings Report?
12:36pm, Wednesday, 04'th Dec 2024
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Krystal Biotech to Present at Upcoming Investor Conferences
07:00am, Wednesday, 27'th Nov 2024
PITTSBURGH, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that Krish S. Krishnan, Chairman and
Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference
07:00am, Wednesday, 06'th Nov 2024
PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in
Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction
03:01pm, Tuesday, 05'th Nov 2024
KRYS beat on both earnings and sales in the third quarter of 2024. Lead drug Vyjuvek's launch in the United States shows strong uptake.
Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Transcript
03:31pm, Monday, 04'th Nov 2024
Krystal Biotech, Inc. (NASDAQ:KRYS ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Stéphane Paquette - VP, Corporate Development Krish Krishnan - Chairman and CEO
Krystal Biotech, Inc. (KRYS) Beats Q3 Earnings and Revenue Estimates
10:10am, Monday, 04'th Nov 2024
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to loss of $0.67 per share a year ago.
Krystal Biotech, Inc. (KRYS) to Report Q3 Results: Wall Street Expects Earnings Growth
11:05am, Monday, 28'th Oct 2024
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024
07:00am, Monday, 28'th Oct 2024
PITTSBURGH, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its third quarter
All You Need to Know About Krystal Biotech (KRYS) Rating Upgrade to Buy
01:00pm, Friday, 18'th Oct 2024
Krystal Biotech (KRYS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On
04:58pm, Monday, 14'th Oct 2024
The company anticipates significant Q4 2024 data releases for KB707 in solid tumors and KB408 in AATD lung disease, potentially boosting shareholder value. Jeune Therapeutics, a subsidiary, shows prom
Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference
07:00am, Friday, 13'th Sep 2024
PITTSBURGH, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in
Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
07:00am, Friday, 06'th Sep 2024
PITTSBURGH, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in
